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INTRODUCTION
Liposarcomas (LPS) are malignant tumors of adipocytic
differentiation. Well-differentiated liposarcoma (WDL)/atypical
lipomatous tumor and dedifferentiated liposarcoma (DDL) together
comprise the largest subgroup of liposarcomas. They occur most
commonly in middle-aged to older adults typically within the
retroperitoneum or proximal extremities. (1) Symptoms suspicious for
liposarcoma include weight gain up to 10-20 lbs. Tumors on the arms
or thighs might easily be noticeable, however, abdominal tumors can
often go unnoticed. (2)

Figure 1. CTabdomen/pelvis
without contrast:
demonstrated a 26
x 16 x 20 cm
lobulated
heterogeneous
mesenteric mass
centered in the
right of midline in
the mid-abdomen,
confluent with
small bowel loops

➢ WDL: does not metastasize, but can dedifferentiate to DDL
➢ DDL: more aggressive clinical behavior, with greater likelihood for
local recurrence and capacity for metastasis. It typically has the
appearance of undifferentiated pleomorphic or spindle cell sarcoma.
Both sarcomas are associated with high-level amplifications in
chromosome 12q13-15, which includes CDK4 and MDM2 cell cycle
oncogenes (3)

CASE DESCRIPTION
64-year-old female with PMH of PE on Eliquis, s/p IVC filter
presents with abdominal discomfort, subjective weight gain and
bilateral leg swelling. Examination showed a distended abdomen
and bilaterally tender edematous legs.
Doppler ultrasound of lower extremities showed extensive DVTs.
Patient developed oliguria and AKI, ultrasound of kidneys was
obtained, showing two large masses in abdomen and pelvis. CT
abdomen/pelvis demonstrated mesenteric mass measuring 26 cm
in right mid-abdomen with multiple smaller masses. IR biopsy
showed malignant cells of spindled and epithelioid features.
Molecular studies were positive for MDM2 amplification, with
focal weak staining for CD10 and inhibin. Features were indicative
of dedifferentiated liposarcoma given presence of MDM2.
Patient was not a surgical candidate but was a candidate for
systemic chemotherapy and received one cycle of Adriamycin,
Ifosfamide, and Mesna (AIM) for treatment of dedifferentiated
liposarcoma; however, course was complicated by ifosfamideinduced encephalopathy. Patient received palliative radiation, and
unfortunately, expired secondary to cardiac arrest from suspected
pulmonary embolism.

DISCUSSION

IMAGING

Figure 2. CTabdomen/pelvis:
shows smaller
mesenteric masses
adjacent to the
dominant lesion,
measuring up to 5.8
cm in left
midabdomen, 2.1
cm in right abdomen
and 2.9 cm in right
aspect of the pelvis
along right iliac
chain

DDL tumors are have six-fold the rate of local and metastatic
recurrence and disease-specific mortality than that of WDL tumors
(2)
Due to the rarity of these tumors and complexity of their treatment,
approach to treatment of liposarcoma is multidisciplinary.
➢ Surgical resection is traditionally the only potentially curative
option, typically indicated for small, low-grade and potentially
resectable WDL tumors
➢ Perioperative radiotherapy has been reported to reduce local
recurrence in retroperitoneal LPS (3)
➢ RT and/or chemotherapy is used to relieve symptoms in patients
with unresectable local and/or metastatic LPS. Anthracyclinebased therapy including doxorubicin with ifosfamide, given with
mesna is preferred treatment (3,5).
➢ Investigational therapies inhibiting MDM2 and CKD4
(palbociclib, rribociclib), as well as immunotherapy
(pembrolizumab) are currently being researched (2,3).

CONCLUSIONS
➢ Signs and symptoms that can point a clinician towards a malignant
liposarcoma include abdominal discomfort and weight gain;
however, they are typically asymptomatic until they are large
enough to compress or invade surrounding structures
➢ DDL is a focal outgrowth from precursor WDL lesions; therefore,
early detection of these tumors is key to prompt diagnosis and
management.

PHYSIOLOGY
Gene amplification of
MDM2, which binds and
inactivates TP53, results in
uncontrolled cell growth in
response to cell damage
and signals that typically
trigger TP43 to cause cell
cycle arrest. (4)
MDM2 is amplified in
nearly 100% of patients,
and CDK4 is co-amplified
in over 90% of patients.
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